Warda Mustfa¹ and Hina Ayub²*

¹PhD Scholar, Department of School of Space and Earth Science, University of Science and Technology of China, Hefei, Anhui, China
²BS Zoology, University of Narowal, Pakistan

*Corresponding Author: Hina Ayub, BS Zoology, University of Narowal, Pakistan.

Received: April 29, 2021; Published: June 08, 2021

Abstract

  Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) affects the cells by ACE, leading to infect the human respiratory system severely. Recently investigated that COVID-19 also damage the Cardiovascular System, leading to cause severe myocardial injury. The increased mortality and morbidity in COVID-19 patients are mainly because of hypertension. This paper interprets the relationship between COVID-19 with cardiovascular damage, hypertension (HTN), ACE, blood pressure, CK-MB, and Lipid Profile. Hypertension (HTN) continues to be a strong and widespread risk factor for IHD.

Keywords: COVID-19; Cardiovascular Disease; Angiotensin-converting Enzyme; CoV-2; Hypertension; Blood Pressure

References

1. Song Z., et al. “From SARS to MERS, thrusting coronaviruses into the spotlight”. Viruses 11 (2019): E59.
2. Zhuo P., et al. “A pneumonia outbreak associated with a new coronavirus of probable bat origin”. Nature (2020): 7.
3. Pearson H., et al. “SARS: what have we learned?” Nature6945 (2003): 121-126.
4. Drosten C., et al. “Identification of a novel coronavirus in patients with the severe acute respiratory syndrome”. The New England Journal of Medicine20 (2003): 1967-1976.
5. World Health Organisation. “A cumulative number of reported probable cases of SARS” (2003).
6. Enserink M. “The big question now: will it be back”. Science5631 (2003): 299.
7. World Health Organisation. “Announcement of suspected SARS case in southern China” (2004).
8. Lee N., et al. “A major outbreak of severe acute respiratory syndrome in Hong Kong”. The New England Journal of Medicine20 (2003): 1986-1994.
9. Alexander LK., et al. “An experimental model for dilated cardiomyopathy after rabbit coronavirus infection”. Journal of Infectious Diseases 5 (1992): 978-985.
10. Small JD., et al. “Rabbit cardiomyopathy associated with a virus antigenically related to human coronavirus strain 229E”. American Journal of Pathology3 (1979): 709-729.
11. Alexander LK., et al. “Electrocardiographic changes following rabbit coronavirus-induced myocarditis and dilated cardiomyopathy”. Advances in Experimental Medicine and Biology 342 (1993): 365-370.
12. Drazen JM. “SARS—looking back over the first 100 days”. The New England Journal of Medicine4 (2003): 319-320.
13. Turner AJ., et al. “ACE2: from vasopeptidase to SARS virus receptor”. Trends in Pharmacology Science6 (2004): 291-294.
14. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. Lancet 395 (2020): 497-506.
15. Wong CK., et al. “Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome”. Clinical and Experimental Immunology 1 (2004): 95-103.
16. Oudit GY., et al. “SARS coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS”. European Journal of Clinical Investigation 7 (2009): 618-625.
17. Kreutz RE., et al. “Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19 European Society of Hypertension COVID-19 Task Force Review of Evidence”. Cardiovascular Research (2019).
18. Wu L., et al. “SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management”. Biochemistry Pharmacology 178 (2020): 114114.
19. Nishiga M., et al. “COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives”. Nature Reviews Cardiology 17 (2020): 543-558.
20. Wang D., et al. “Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China”. JAMA11 (2020): 1061-1069.
21. Landesberg G., et al. “Association of cardiac troponin, CK-MB, and postoperative myocardial ischemia with long-term survival after major vascular surgery”. Journal of the American College of Cardiology9 (2003): 1547-54.
22. Tabas I., et al. “Sub endothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications”. Circulation 16 (2007): 1832-1844.
23. Hansson GK. “Inflammation, atherosclerosis, and coronary artery disease”. The New England Journal of Medicine 352 (2005): 1685-1695.
24. Libby P and Simon DI. “Inflammation and thrombosis: the clot thickens”. Circulation 1003 (2001): 1718-1720.
25. Wu C., et al. “Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China”. JAMA Internal Medicine (2020).
26. Zhou F., et al. “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study”. Lancet (2020): S0140-6736 (20)305663.
27. European Society of Cardiology. “Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers” (2020).
28. American Heart Association. “HFSA/ACC/AHA statement addresses concern reusing RAAS antagonists in COVID-19” (2020).
29. Crawford MH. “Chapter 6. Chronic ischemic heart disease”. In: Crawford MH, editor. Current diagnosis and treatment: cardiology,4e. New York: McGraw-Hill (2014).
30. Mohrman DE and Heller L. “Chapter 1. Overview of the cardiovascular system”. In: Mohrman DE, Heller L, editors. Cardiovascular physiology, 8e. New York: McGraw-Hill (2014).
31. Agbor-Etang BB and Setaro JF. “Management of Hypertension in Patients with Ischemic Heart Disease”. Current Cardiology Reports12 (2015): 119.
32. Alhogbani T. “Acute myocarditis associated with novel Middle East respiratory syndrome coronavirus”. Annals of Saudi Medicine 1 (2016): 78-80.
33. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. Lancet 10223 (2020): 497-506.
34. Wu Q., et al. “Altered lipid metabolism in recovered SARS patients twelve years after infection”. Scientific Report 7 (2017): 9110.
35. Zheng YY., et al. “COVID-19, and the cardiovascular system”. Nature Reviews Cardiology5 (2020): 259-260.
36. Corrales-Medina VF., et al. “Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease”. JAMA 313 (2015): 264.
37. J Wang H., et al. “Cardiac complications associated with the influenza viruses A subtype H7N9 or pandemic H1N1 in critically ill patients under intensive care”. Brazilian Journal of Infectious Diseases 1 (2017): 12-18.
38. Drazner MH. “The progression of hypertensive heart disease”. Circulation3 (2011): 327-334.
39. Chhikara BS., et al. “Coronavirus SARS-CoV-2 disease COVID-19: Infection, prevention, and clinical advances of the prospective chemical drug therapeutics”. Chemical Biology Letters1 (2020): 63-72.
40. Adedeji AO., et al. “Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms”. Journal of Virology14 (2013): 8017-8028.
41. Wrap D., et al. “Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation”. Science 6483 (2020): 1260.
42. Walls AC., et al. “Structure-function, and antigenicity of the SARS-CoV-2 spike glycoprotein”. Cell 181 (2020): 281-292.
43. Joyce E., et al. “Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review”. European Heart Journal: Acute Cardiovascular Care 1 (2013): 77-83.
44. Gurwitz D. “Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics”. Drug Development Research (2020).
45. US FDA. Fact sheet for health care providers: emergency use authorization (EUA) of remdesivir (GS-5734™) (2020).
46. Zhong Q., et al. “Antiviral activity of Arbidol against Coxsackievirus B5 in vitro and in vivo”. Archives of Virology 4 (2009): 601-607.
47. Vankadari N. “Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking the trimerization of viral spike glycoprotein?” International Journal of Antimicrobial Agents 28 (2020): 105998.
48. Reyskens KM and Essop MF. “HIV protease inhibitors and onset of cardiovascular diseases: A central role for oxidative stress and dysregulation of the ubiquitin-proteasome system”. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease2 (2014): 256-268.

Citation

Citation: Warda Mustfa and Hina Ayub. “Covid-19 Infection and Cardiovascular System: A-Review". Acta Scientific Veterinary Sciences 3.7 (2021): 17-24.

Copyright

Copyright: © 2021 Warda Mustfa and Hina Ayub. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.